| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |